TransMedics Group (NASDAQ:TMDX) Stock Price Up 7.4% – Should You Buy?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) were up 7.4% during mid-day trading on Monday . The stock traded as high as $86.60 and last traded at $86.54. Approximately 907,876 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 1,332,665 shares. The stock had previously closed at $80.58.

Wall Street Analyst Weigh In

Several research firms recently commented on TMDX. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Up 0.4 %

The firm has a 50 day moving average price of $71.46 and a 200-day moving average price of $80.72. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.93 billion, a PE ratio of 92.75 and a beta of 2.14.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC increased its holdings in shares of TransMedics Group by 132.2% in the 1st quarter. SG Americas Securities LLC now owns 14,126 shares of the company’s stock valued at $950,000 after acquiring an additional 8,043 shares during the period. GAMMA Investing LLC increased its stake in TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company’s stock valued at $105,000 after purchasing an additional 1,324 shares during the period. Sugar Maple Asset Management LLC purchased a new stake in shares of TransMedics Group in the first quarter valued at about $740,000. NBC Securities Inc. acquired a new stake in shares of TransMedics Group during the first quarter worth about $25,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of TransMedics Group during the fourth quarter worth about $4,131,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.